Nkarta, Inc. (NKTX)
NASDAQ
Market Cap
$173.25M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
10 of 951
Rank in Industry
8 of 544
Largest Insider Buys in Sector
NKTX Stock Price History Chart
NKTX Stock Performance
About Nkarta, Inc.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Insider Activity of Nkarta, Inc.
Over the last 12 months, insiders at Nkarta, Inc. have bought $50M and sold $419,335 worth of Nkarta, Inc. stock.
On average, over the past 5 years, insiders at Nkarta, Inc. have bought $149.67M and sold $1.61M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $900M. George Simeon (director) — $60M.
The last purchase of 3,000,000 shares for transaction amount of $30M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑03‑27.
List of Insider Buy and Sell Transactions, Nkarta, Inc.
| 2024-07-16 | Sale | Chief Legal Officer | 3,396 0.0065% | $8.00 | $27,168 | -50.88% | ||
| 2024-06-18 | Sale | Chief Executive Officer | 1,770 0.0022% | $5.60 | $9,912 | -24.38% | ||
| 2024-06-18 | Sale | Chief Scientific Officer | 456 0.0006% | $5.60 | $2,554 | -24.38% | ||
| 2024-06-18 | Sale | Chief Medical Officer | 456 0.0006% | $5.60 | $2,554 | -24.38% | ||
| 2024-06-18 | Sale | Chief Legal Officer | 727 0.0009% | $5.60 | $4,071 | -24.38% | ||
| 2024-06-18 | Sale | Chief Technical Officer | 229 0.0003% | $5.60 | $1,282 | -24.38% | ||
| 2024-03-27 | 3M 5.4767% | $10.00 | $30M | -51.38% | ||||
| 2024-03-27 | director | 2M 3.6511% | $10.00 | $20M | -51.38% | |||
| 2024-03-01 | Sale | Chief Technical Officer | 8,367 0.0167% | $12.51 | $104,671 | -55.92% | ||
| 2024-02-12 | Sale | Chief Scientific Officer | 4,143 0.0088% | $12.00 | $49,716 | -47.04% | ||
| 2024-01-16 | Sale | Chief Executive Officer | 9,697 0.02% | $8.74 | $84,752 | -25.76% | ||
| 2024-01-16 | Sale | Chief Scientific Officer | 4,560 0.0094% | $8.74 | $39,854 | -25.76% | ||
| 2024-01-16 | Sale | Chief Medical Officer | 3,552 0.0073% | $8.74 | $31,044 | -25.76% | ||
| 2024-01-16 | Sale | Chief Legal Officer | 4,554 0.0094% | $8.74 | $39,802 | -25.76% | ||
| 2024-01-16 | Sale | Chief Technical Officer | 2,512 0.0052% | $8.74 | $21,955 | -25.76% | ||
| 2023-08-21 | Sale | Chief Medical Officer | 1,331 0.0027% | $1.83 | $2,436 | +246.70% | ||
| 2023-06-20 | Sale | Chief Executive Officer | 1,704 0.0035% | $4.85 | $8,264 | -6.16% | ||
| 2023-06-20 | Sale | Chief Scientific Officer | 439 0.0009% | $4.85 | $2,129 | -6.16% | ||
| 2023-06-20 | Sale | See Remarks | 526 0.0011% | $4.85 | $2,551 | -6.16% | ||
| 2023-06-20 | Sale | Chief Medical Officer | 439 0.0009% | $4.85 | $2,129 | -6.16% |
Insider Historical Profitability
<0.0001%
| RA CAPITAL MANAGEMENT, L.P. | 10050818 14.2426% | $2.46 | 3 | 0 | <0.0001% | |
| George Simeon | director | 1548341 2.1941% | $2.46 | 2 | 0 | <0.0001% |
| HASTINGS PAUL J | Chief Executive Officer | 240737 0.3411% | $2.46 | 0 | 8 | |
| Trager James | Chief Scientific Officer | 150959 0.2139% | $2.46 | 0 | 10 | |
| Shook David | Chief Medical Officer | 116524 0.1651% | $2.46 | 0 | 5 | |
| Hager Alicia J. | Chief Legal Officer | 103819 0.1471% | $2.46 | 0 | 5 | |
| Brandenberger Ralph | Chief Technical Officer | 79743 0.113% | $2.46 | 0 | 13 | |
| GLAXOSMITHKLINE PLC | 3150732 4.4648% | $2.46 | 1 | 0 | <0.0001% | |
| MAKOWER JOSHUA | 10 percent owner | 2902115 4.1125% | $2.46 | 1 | 0 | <0.0001% |
| SANDELL SCOTT D | 10 percent owner | 2902115 4.1125% | $2.46 | 1 | 0 | <0.0001% |
| BASKETT FOREST | 10 percent owner | 2902115 4.1125% | $2.46 | 1 | 0 | <0.0001% |
| Sonsini Peter W. | 10 percent owner | 2902115 4.1125% | $2.46 | 1 | 0 | <0.0001% |
| Florence Anthony A. Jr. | 10 percent owner | 2902115 4.1125% | $2.46 | 1 | 0 | <0.0001% |
| New Enterprise Associates 15, L.P. | 10 percent owner | 2902115 4.1125% | $2.46 | 1 | 0 | <0.0001% |
| Makhzoumi Mohamad | 10 percent owner | 2902115 4.1125% | $2.46 | 1 | 0 | <0.0001% |
| Novo Holdings A/S | 10 percent owner | 2793865 3.9591% | $2.46 | 1 | 0 | <0.0001% |
| Flynn James E | director | 1209936 1.7145% | $2.46 | 1 | 0 | <0.0001% |
| Mahmood Nadir | See Remarks | 85776 0.1215% | $2.46 | 0 | 9 | |
| Rajangam Kanya | Chief Medical Officer | 0 0% | $2.46 | 0 | 1 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| RA Capital Management, L.P. | $116.8M | 15.33 | 10.81M | +38.44% | +$32.43M | 0.12 | |
| Boxer Capital, LLC | $60.62M | 7.96 | 5.61M | +289.4% | +$45.05M | 1.24 | |
| Deerfield Management | $56.15M | 7.37 | 5.19M | +52.77% | +$19.39M | 0.14 | |
| Adage Capital Partners Gp L L C | $41.08M | 5.39 | 3.8M | +10.14% | +$3.78M | 0.08 | |
| Samsara Biocapital Llc | $40.73M | 5.35 | 3.77M | +31.38% | +$9.73M | 6.35 | |
| Nea Management Company Llc | $38.58M | 5.06 | 3.57M | 0% | +$0 | 0.18 | |
| Sr One Capital Management Lp | $36.03M | 4.73 | 3.33M | +150% | +$21.62M | 9.9 | |
| Commodore Capital, LP | $34.21M | 4.49 | 3.17M | +15.93% | +$4.7M | 0.13 | |
| BlackRock | $30.54M | 4.01 | 2.83M | +8.71% | +$2.45M | <0.01 | |
| Ecor1 Capital Llc | $21.62M | 2.84 | 2M | New | +$21.62M | 0.15 | |
| The Vanguard Group | $21.26M | 2.79 | 1.97M | +26% | +$4.39M | <0.0001 | |
| T Rowe Price Investment Management Inc | $14.65M | 1.92 | 1.36M | +192.83% | +$9.65M | 0.01 | |
| Cormorant Asset Management Lp | $14.59M | 1.92 | 1.35M | New | +$14.59M | 0.68 | |
| Wasatch Advisors | $12.63M | 1.66 | 1.17M | -44.35% | -$10.07M | 0.07 | |
| Ameriprise Financial | $12.11M | 1.59 | 1.12M | +10,800.12% | +$12M | <0.01 | |
| Janus Henderson | $9.07M | 1.19 | 838,839 | New | +$9.07M | 0.01 | |
| Renaissance Technologies | $8.81M | 1.16 | 814,872 | +23.88% | +$1.7M | 0.01 | |
| Geode Capital Management | $8.81M | 1.16 | 814,408 | +24.58% | +$1.74M | <0.01 | |
| OrbiMed | $8.65M | 1.14 | 800,000 | New | +$8.65M | 0.07 | |
| State Street | $6.8M | 0.89 | 629,155 | +2.83% | +$187,077.87 | <0.0001 | |
| Woodline Partners LP | $6.76M | 0.89 | 625,129 | New | +$6.76M | 0.06 | |
| Tang Capital Management, LLC | $5.95M | 0.78 | 550,000 | 0% | +$0 | 0.02 | |
| Alyeska Investment Group L P | $5.81M | 0.76 | 537,580 | +19.27% | +$938,837.72 | 0.04 | |
| Citadel Advisors LLC | $4.56M | 0.6 | 422,234 | New | +$4.56M | <0.01 | |
| Schonfeld Group | $4.33M | 0.57 | 400,100 | New | +$4.33M | 0.03 | |
| JPMorgan Chase | $3.73M | 0.49 | 345,159 | -3.37% | -$130,303.75 | <0.0001 | |
| Northern Trust | $3.43M | 0.45 | 317,227 | -1.1% | -$38,072.82 | <0.01 | |
| Soleus Capital Management, L.P. | $3.24M | 0.43 | 300,000 | New | +$3.24M | 0.01 | |
| Parkman Healthcare Partners Llc | $2.72M | 0.36 | 252,028 | New | +$2.72M | 0.34 | |
| Two Sigma | $2.68M | 0.35 | 248,147 | +77.32% | +$1.17M | <0.01 | |
| Octagon Capital Advisors LP | $2.59M | 0.34 | 240,000 | New | +$2.59M | 0.01 | |
| Nuveen | $2.52M | 0.33 | 233,090 | +153.56% | +$1.53M | <0.01 | |
| CIBC World Markets | $2.16M | 0.28 | 200,000 | New | +$2.16M | 0.01 | |
| Cibc World Markets Corp | $2.16M | 0.28 | 200,000 | New | +$2.16M | 0.01 | |
| Marshall Wace | $2.01M | 0.26 | 185,869 | -25.85% | -$700,466.42 | <0.01 | |
| Morgan Stanley | $1.92M | 0.25 | 177,595 | -17.4% | -$404,488.59 | <0.0001 | |
| Bridgeway Capital Management | $1.83M | 0.24 | 169,467 | -55.34% | -$2.27M | 0.03 | |
| Wellington Management Company | $1.4M | 0.18 | 129,374 | New | +$1.4M | <0.0001 | |
| Walleye Capital | $1.34M | 0.18 | 124,119 | New | +$1.34M | <0.01 | |
| Jane Street Capital | $1.32M | 0.17 | 122,027 | -16.55% | -$261,645.27 | <0.01 | |
| Squarepoint Ops LLC | $1.05M | 0.14 | 97,196 | +165.26% | +$654,588.89 | <0.01 | |
| Dimensional Fund Advisors | $1.04M | 0.14 | 96,663 | +70.82% | +$433,221.55 | <0.0001 | |
| BNY Mellon | $1.03M | 0.14 | 95,550 | -9.84% | -$112,661.33 | <0.0001 | |
| Stifel | $1.02M | 0.13 | 93,934 | -54.68% | -$1.23M | <0.01 | |
| Charles Schwab | $966,717.00 | 0.13 | 89,428 | +29.4% | +$219,648.46 | <0.0001 | |
| Ubs Oconnor Llc | $864,800.00 | 0.11 | 80,000 | New | +$864,800.00 | 0.04 | |
| Susquehanna Fundamental Investments Llc | $788,027.00 | 0.1 | 72,898 | New | +$788,027.00 | 0.04 | |
| AllianceBernstein | $722,324.00 | 0.1 | 66,820 | 0% | +$0 | <0.0001 | |
| Fidelity Investments | $702,088.00 | 0.09 | 64,948 | -53.18% | -$797,399.79 | <0.0001 | |
| Goldman Sachs | $568,692.00 | 0.08 | 52,608 | -33.55% | -$287,113.36 | <0.0001 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.